

# Andreas Geier

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7001730/publications.pdf>

Version: 2024-02-01

74  
papers

5,903  
citations

136950

32  
h-index

82547

72  
g-index

83  
all docs

83  
docs citations

83  
times ranked

7475  
citing authors

#	ARTICLE	IF	CITATIONS
1	Diagnostic accuracy of non-invasive tests for advanced fibrosis in patients with NAFLD: an individual patient data meta-analysis. <i>Gut</i> , 2022, 71, 1006-1019.	12.1	195
2	Liraglutide + PYY3-36 Combination Therapy Mimics Effects of Roux-en-Y Bypass on Early NAFLD Whilst Lacking-Behind in Metabolic Improvements. <i>Journal of Clinical Medicine</i> , 2022, 11, 753.	2.4	4
3	Real-World Burden of Nonalcoholic Steatohepatitis. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 1020-1029.e7.	4.4	21
4	From the origin of NASH to the future of metabolic fatty liver disease. <i>Gut</i> , 2021, 70, 1570-1579.	12.1	43
5	An update on drug development for the treatment of nonalcoholic fatty liver disease – from ongoing clinical trials to future therapy. <i>Expert Review of Clinical Pharmacology</i> , 2021, 14, 333-340.	3.1	20
6	Non-alcoholic fatty liver disease and psoriasis – is there a shared proinflammatory network?. <i>JDDG - Journal of the German Society of Dermatology</i> , 2021, 19, 517-528.	0.8	22
7	Effect of high altitude on human postprandial 13 C octanoate metabolism, intermediary metabolites, gastrointestinal peptides, and visceral perception. <i>Neurogastroenterology and Motility</i> , 2021, , e14225.	3.0	0
8	Screening for nonalcoholic fatty liver disease-when, who and how?. <i>World Journal of Gastroenterology</i> , 2021, 27, 5803-5821.	3.3	18
9	Liver Disease, Nonalcoholic Fatty. , 2020, , 408-413.		1
10	GALAD Score Detects Early Hepatocellular Carcinoma in an International Cohort of Patients With Nonalcoholic Steatohepatitis. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 728-735.e4.	4.4	167
11	Transcriptional control of cells by vitamin D and its role in liver health and disease. , 2020, , 651-671.		0
12	The European NAFLD Registry: A real-world longitudinal cohort study of nonalcoholic fatty liver disease. <i>Contemporary Clinical Trials</i> , 2020, 98, 106175.	1.8	71
13	The <sup>13</sup> C methactin breath test is non-inferior to liver biopsy in predicting liver-related death and transplantation: A 7-year prospective follow-up study in 132 patients with chronic hepatitis C infection. <i>GastroHep</i> , 2020, 2, 344-350.	0.6	2
14	Liver Phenotypes of European Adults Heterozygous or Homozygous for Pi*Z Variant of AAT (Pi*Z vs Pi*ZZ) in the Overlooked	1.3	63
15	Non-invasive diagnosis of patients with "at-risk" NAFLD : only fibrosis counts?. <i>Gut</i> , 2020, 69, 1164-1165.	12.1	7
16	Heterozygous carriage of the alpha1-antitrypsin Pi*Z variant increases the risk to develop liver cirrhosis. <i>Gut</i> , 2019, 68, 1099-1107.	12.1	100
17	Animal models of NAFLD from a hepatologist's point of view. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2019, 1865, 943-953.	3.8	132
18	Elevated oxysterol levels in human and mouse livers reflect nonalcoholic steatohepatitis. <i>Journal of Lipid Research</i> , 2019, 60, 1270-1283.	4.2	37

#	ARTICLE	IF	CITATIONS
19	The Patient Perspectives on Future Therapeutic Options in NASH and Patient Needs. <i>Frontiers in Medicine</i> , 2019, 6, 61.	2.6	26
20	SAT-357-Tropifexor, a farnesoid X receptor agonist for the treatment of non-alcoholic steatohepatitis: Interim results based on baseline body mass index from first two parts of Phase 2b study FLIGHT-FXR. <i>Journal of Hepatology</i> , 2019, 70, e796-e797.	3.7	19
21	Intestinal vitamin D receptor modulates lipid metabolism, adipose tissue inflammation and liver steatosis in obese mice. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2019, 1865, 1567-1578.	3.8	30
22	Non-invasive assessment of NAFLD as systemic disease – A machine learning perspective. <i>PLoS ONE</i> , 2019, 14, e0214436.	2.5	56
23	Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial. <i>Lancet, The</i> , 2019, 394, 2184-2196.	13.7	818
24	A 2-step fast-track elastometry service for advanced workup of nonalcoholic fatty liver disease (NAFLD) patients – single-center real-world experience of outpatient clinical practice. <i>Zeitschrift Fur Gastroenterologie</i> , 2019, 57, 1209-1217.	0.5	8
25	Epigenetic events involved in organic cation transporter 1-dependent impaired response of hepatocellular carcinoma to sorafenib. <i>British Journal of Pharmacology</i> , 2019, 176, 787-800.	5.4	39
26	Beneficial Effects of Vitamin D Treatment in an Obese Mouse Model of Non-Alcoholic Steatohepatitis. <i>Nutrients</i> , 2019, 11, 77.	4.1	33
27	Could inherited predisposition drive non-obese fatty liver disease? Results from German tertiary referral centers. <i>Journal of Human Genetics</i> , 2018, 63, 621-626.	2.3	29
28	Bile acids in nonalcoholic steatohepatitis: Pathophysiological driving force or innocent bystanders?. <i>Hepatology</i> , 2018, 67, 464-466.	7.3	15
29	Fecal SCFAs and SCFA-producing bacteria in gut microbiome of human NAFLD as a putative link to systemic T cell activation and advanced disease. <i>United European Gastroenterology Journal</i> , 2018, 6, 1496-1507.	3.8	190
30	Serum IP-10 levels and increased DPPiV activity are linked to circulating CXCR3+ T cells in cholestatic HCV patients. <i>PLoS ONE</i> , 2018, 13, e0208225.	2.5	3
31	Treatment of non-alcoholic steatohepatitis patients with vitamin D: a double-blinded, randomized, placebo-controlled pilot study. <i>Scandinavian Journal of Gastroenterology</i> , 2018, 53, 1114-1120.	1.5	41
32	Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016–2030. <i>Journal of Hepatology</i> , 2018, 69, 896-904.	3.7	1,157
33	Emerging therapies for NASH - the future is now. <i>Expert Review of Clinical Pharmacology</i> , 2017, 10, 467-469.	3.1	15
34	The ABCB4 p.T175A variant as potential modulator of hepatic fibrosis in patients with chronic liver diseases: Looking beyond the cholestatic realm. <i>Hepatology</i> , 2017, 66, 666-667.	7.3	7
35	Changes in drug transport and metabolism and their clinical implications in non-alcoholic fatty liver disease. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2017, 13, 625-640.	3.3	23
36	Toxic drug-induced liver failure during therapy of rheumatoid arthritis with tocilizumab subcutaneously: a case report. <i>Rheumatology</i> , 2017, 56, 1628-1629.	1.9	11

#	ARTICLE	IF	CITATIONS
37	Combined effects of the PNPLA3 rs738409, TM6SF2 rs58542926, and MBOAT7 rs641738 variants on NAFLD severity: a multicenter biopsy-based study. <i>Journal of Lipid Research</i> , 2017, 58, 247-255.	4.2	159
38	Non-Alcoholic Steatohepatitis: From Pathophysiology to Novel Therapies. <i>Digestive Diseases</i> , 2016, 34, 356-363.	1.9	25
39	Alterations in Enterohepatic Fgf15 Signaling and Changes in Bile Acid Composition Depend on Localization of Murine Intestinal Inflammation. <i>Inflammatory Bowel Diseases</i> , 2016, 22, 2382-2389.	1.9	21
40	Feasibility of liver stiffness measurement in morbidly obese patients undergoing bariatric surgery using XL probe. <i>Scandinavian Journal of Gastroenterology</i> , 2016, 51, 1263-1268.	1.5	21
41	Progression from Nonalcoholic Fatty Liver to Nonalcoholic Steatohepatitis Is Marked by a Higher Frequency of Th17 Cells in the Liver and an Increased Th17/Resting Regulatory T Cell Ratio in Peripheral Blood and in the Liver. <i>Journal of Immunology</i> , 2016, 196, 97-105.	0.8	210
42	Farnesoid X receptor-dependent and -independent pathways mediate the transcriptional control of human fibroblast growth factor 19 by vitamin A. <i>Biochimica Et Biophysica Acta - Gene Regulatory Mechanisms</i> , 2016, 1859, 381-392.	1.9	10
43	Influence of Ribavirin Serum Levels on Outcome of Antiviral Treatment and Anemia in Hepatitis C Virus Infection. <i>PLoS ONE</i> , 2016, 11, e0158512.	2.5	9
44	Molecular changes in hepatic metabolism and transport in cirrhosis and their functional importance. <i>World Journal of Gastroenterology</i> , 2016, 22, 72.	3.3	34
45	Ulcerating Ileocolitis in Severe Amatoxin Poisoning. <i>Case Reports in Gastrointestinal Medicine</i> , 2015, 2015, 1-4.	0.3	3
46	Mechanisms of enterohepatic fibroblast growth factor 15/19 signaling in health and disease. <i>Cytokine and Growth Factor Reviews</i> , 2015, 26, 625-635.	7.2	55
47	Protective effects of farnesoid X receptor (FXR) on hepatic lipid accumulation are mediated by hepatic FXR and independent of intestinal FGF15 signal. <i>Liver International</i> , 2015, 35, 1133-1144.	3.9	104
48	Performance of Serum microRNAs -122, -192 and -21 as Biomarkers in Patients with Non-Alcoholic Steatohepatitis. <i>PLoS ONE</i> , 2015, 10, e0142661.	2.5	116
49	Non-Alcoholic Fatty Liver Disease. <i>Deutsches A&amp;#x0308;rztblatt International</i> , 2014, 111, 447-52.	0.9	134
50	Hepatitis B virus: The "metabolovirus" hijacks cholesterol and bile acid metabolism. <i>Hepatology</i> , 2014, 60, 1458-1460.	7.3	29
51	Effect of drug transporter pharmacogenetics on cholestasis. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2014, 10, 1533-1551.	3.3	21
52	Elderly age is not a negative predictive factor for virological response to therapy with pegylated interferon- $\alpha$ and ribavirin in chronic hepatitis C virus patients. <i>Liver International</i> , 2014, 34, 551-557.	3.9	13
53	Downregulation of duodenal SLC transporters and activation of proinflammatory signaling constitute the early response to high altitude in humans. <i>American Journal of Physiology - Renal Physiology</i> , 2014, 307, G673-G688.	3.4	29
54	Free fatty acids repress small heterodimer partner (SHP) activation and adiponectin counteracts bile acid-induced liver injury in superobese patients with nonalcoholic steatohepatitis. <i>Hepatology</i> , 2013, 57, 1394-1406.	7.3	197

#	ARTICLE	IF	CITATIONS
55	Adaptation of iron transport and metabolism to acute high-altitude hypoxia in mountaineers. <i>Hepatology</i> , 2013, 58, 2153-2162.	7.3	71
56	Shedding new light on vitamin D and fatty liver disease. <i>Journal of Hepatology</i> , 2011, 55, 273-275.	3.7	32
57	A common polymorphism in the <i>ABCB11</i> gene is associated with advanced fibrosis in hepatitis C but not in non-alcoholic fatty liver disease. <i>Clinical Science</i> , 2011, 120, 287-296.	4.3	44
58	Bile acid retention and activation of endogenous hepatic farnesoid-X-receptor in the pathogenesis of fatty liver disease in ob/ob-mice. <i>Biological Chemistry</i> , 2010, 391, 1441-9.	2.5	22
59	Hepatocyte nuclear factor-4 $\beta$ is a central transactivator of the mouse <i>Ntcp</i> gene. <i>American Journal of Physiology - Renal Physiology</i> , 2008, 295, G226-G233.	3.4	34
60	Fasting induces basolateral uptake transporters of the SLC family in the liver via HNF4 $\beta$ and PGC1 $\beta$ . <i>American Journal of Physiology - Renal Physiology</i> , 2007, 293, G585-G590.	3.4	21
61	Profuse rectal bleeding of no visible cause. <i>Lancet, The</i> , 2007, 369, 1664.	13.7	3
62	Bile acids are $\alpha$ -homeotropic sensors of the functional hepatic capacity and regulate adaptive growth during liver regeneration. <i>Hepatology</i> , 2007, 45, 251-253.	7.3	18
63	Principles of hepatic organic anion transporter regulation during cholestasis, inflammation and liver regeneration. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , 2007, 1773, 283-308.	4.1	275
64	Mechanisms of Disease: mechanisms and clinical implications of cholestasis in sepsis. <i>Nature Reviews Gastroenterology &amp; Hepatology</i> , 2006, 3, 574-585.	1.7	193
65	Cytokine-independent repression of rodent <i>Ntcp</i> in obstructive cholestasis. <i>Hepatology</i> , 2005, 41, 470-477.	7.3	40
66	Cytokine-dependent regulation of hepatic organic anion transporter gene transactivators in mouse liver. <i>American Journal of Physiology - Renal Physiology</i> , 2005, 289, G831-G841.	3.4	94
67	Characterization of organic anion transporter regulation, glutathione metabolism and bile formation in the obese Zucker rat. <i>Journal of Hepatology</i> , 2005, 43, 1021-1030.	3.7	56
68	Occult celiac disease prevents penetrance of hemochromatosis. <i>World Journal of Gastroenterology</i> , 2005, 11, 3323.	3.3	19
69	Effects of proinflammatory cytokines on rat organic anion transporters during toxic liver injury and cholestasis. <i>Hepatology</i> , 2003, 38, 345-354.	7.3	195
70	Regulation of basolateral organic anion transporters in ethinylestradiol-induced cholestasis in the rat. <i>Biochimica Et Biophysica Acta - Biomembranes</i> , 2003, 1609, 87-94.	2.6	76
71	Defense Barriers in the Body: Contribution of Multidrug Resistance-Associated Protein 2. <i>Comments on Modern Biology Part B, Comments on Toxicology</i> , 2003, 9, 201-214.	0.2	0
72	Magnetic resonance imaging and magnetic resonance cholangiopancreaticography for diagnosis and pre-interventional evaluation of a fluid thoracic mass. <i>European Journal of Gastroenterology and Hepatology</i> , 2003, 15, 429-431.	1.6	12

#	ARTICLE	IF	CITATIONS
73	Side effects of budesonide in liver cirrhosis due to chronic autoimmune hepatitis: effect of hepatic metabolism versus portosystemic shunts on a patient complicated with HCC. <i>World Journal of Gastroenterology</i> , 2003, 9, 2681.	3.3	62
74	Regulation of organic anion transporters in a new rat model of acute and chronic cholangitis resembling human primary sclerosing cholangitis. <i>Journal of Hepatology</i> , 2002, 36, 718-724.	3.7	21